Physician profile
Deborah L Eisenmann
NPI 1235227950
$1,406.47
in general payments reported to CMS, 2019-2025
25 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $109 · 2021: $185 · 2023: $164 · 2024: $291 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $844.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $239.65 | 2023-2025 | Spravato, Invega Sustenna |
| Alkermes, INC. | $160.77 | 2019-2021 | |
| Abbvie INC. | $154.28 | 2019-2024 | |
| Pfizer INC. | $124.85 | 2023-2025 | |
| Braeburn INC. | $78.17 | 2023-2025 | Brixadi |
| Insulet Corporation | $75.11 | 2020-2025 | Omnipod |
| Astellas Pharma US INC | $72.39 | 2019-2021 | |
| Novo Nordisk INC | $64.34 | 2023-2024 | |
| Axsome Therapeutics, INC. | $62.15 | 2024-2025 | Auvelity |
| Eisai INC. | $46.91 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $40.96 | 2023 | Rexulti |
| Exact Sciences Corporation | $33.95 | 2025 | The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $29.20 | 2024 | Ingrezza |
| Horizon Therapeutics Plc | $28.66 | 2019-2020 | |
| Gilead Sciences, INC. | $22.73 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomerieux INC | $22.00 | 2025 | Biofire Spotfire Control Station |
| Dexcom, INC. | $21.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.48 | 2023 | Xifaxan |
| Indivior INC. | $19.27 | 2025 | Sublocade |
| Avanir Pharmaceuticals, INC. | $19.09 | 2020 | |
| Mylan Specialty L.P. | $18.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.94 | 2021 | |
| Amgen INC. | $13.41 | 2019 | |
| Visby Medical, INC. | $13.26 | 2025 | Visby Medical Sexual Health Click Test |
| Medtronic Minimed, INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Eisenmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.